New PET material effectively detects multiple cancers, identifying patients for targeted therapy

Nýtt PET-efni greinir á áhrifaríkan hátt mörg krabbamein, greinir sjúklinga fyrir markvissar meðferðir

Graphical abstract. Credit: Journal of Nuclear Medicine (2022). DOI: 10.2967/jnumed.121.263693

A new molecular imaging radiopharmaceutical can accurately detect a wide range of cancers, providing a roadmap for identifying patients who might benefit from targeted radiation therapy. In the largest medical study of its kind, researchers found that out 68Ga-PentixaFor showed high contrast in blood malignancies, small cell lung cancer and adrenal tumors.

This study was published in the November issue of the newspaper Journal of Nuclear Medicine.

The image analyzer 68Ga-PentixaFor is used to detect CXC motif chemokine receptor 4 (CXCR4). Chemokine receptor expression predicts poor prognosis in cancer patients, as it promotes the growth of malignant cells and inhibits the tumor response.

“Knowing which cancers have increased expression of CXCR4 can have a significant impact on clinical tumor staging and subsequently influence patient management and treatment decisions,” said Andreas Buck, director of the Department of Nuclear Medicine at the University Hospital of Würzburg in Würzburg, Germany.

68Ga-PentixaFor PET is of particular interest because it offers a better detection rate of lesions than other imaging modalities, such as MRI, CT and even FDG PET.”

In the study, researchers evaluated 68Ga-Pentixa For acquisition and contrast to determine the appropriate clinical use of CXCR4-directed imaging. Two research sites conducted 68Ga-PentixaFor PET on 690 patients with 35 different types of cancer. Images were interpreted and statistical analyzes performed.

Very high trace uptake was found in patients with multiple myeloma, adrenal carcinoma, mantle cell lymphoma, adrenal adenoma and small cell lung carcinoma. Comparable results were recorded for image contrast.

“These findings suggest clinical scenarios in which 68Ga-PentixaFor PET may prove useful in guiding CXCR4-targeted therapies,” said Buck. “This is particularly important for malignancies that lack a suitable imaging modality. A pivotal phase III trial to continue this study is planned for the second quarter of 2023.”

More information:
Andreas K. Buck et al., Imaging CXC Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematological Tumors Using 68Ga-PentixaFor PET, Journal of Nuclear Medicine (2022). DOI: 10.2967/jnumed.121.263693

Provided by the Society of Nuclear Medicine

Quotation: New PET agent effectively detects multiple cancers, identifies patients for targeted therapy (2022, November 17) Retrieved November 17, 2022 from -cancers.html

This document is subject to copyright. Except for reasonable communications for the purpose of private research or investigation, no part may be reproduced without written permission. The material is provided for informational purposes only.

Leave a Comment

Your email address will not be published. Required fields are marked *